China approved its first domestically designed depression drug for sale in November 2022.
Notes on verification
Confirmed by Luye Pharma's own press release, Chinese state media, industry trade press (BioWorld), and Wikipedia, all consistently citing NMPA approval on November 3, 2022. [cascade flags: wikipedia_dropped_other_sources_exist | tier=bronze indep_score=0.525 clusters=5 claim_tier=notable | framework convergence=partial on NMPA drug approval announcement/registry (upstreams: National Medical Products Administration (NMPA) of China) — publishers independent, evidence may not be | kind=empirical eligibility=high]
Sources
- The US-China chip war is still escalating (seed:technology_and_ai)
- https://www.luye.cn/lvye_en/view.php?id=2108 (corroboration)
- https://www.globaltimes.cn/page/202302/1285816.shtml (corroboration)
- https://www.bioworld.com/articles/691400-luyes-antidepressant-approved-for-marketing-in-china?v=preview (corroboration)
- https://www.sh.chinanews.com.cn/yljk/2022-11-03/104862.shtml (corroboration)
- https://webull.com/news/7585402856258560 (corroboration)